DynaGen Subsidiary Signs Marketing Agreement with Gensia.

CINCINNATI--(BUSINESS WIRE)--June 4, 1999--

Superior Pharmaceutical Co., a subsidiary of DynaGen Inc. (OTC BB:DYGN) (BSE:DYG), announced Friday that it has signed an agreement with Gensia Sicor Pharmaceuticals to co-market Gensia's newly approved Haloperidol Decanoate Injectable.

Under the terms of the agreement, Gensia will manufacture four different strengths of the drug under the Superior label.

"We expect sales in excess of $5 million over a three-year period," said Dennis Smith, president and CEO of Superior Pharmaceuticals. "Haloperidol Decanoate is Superior's second product launch with Gensia Sicor Pharmaceuticals and this agreement demonstrates our commitment to move into co-marketing or joint venture sales relationships with both brand and generic manufacturers. Superior now has over 50 telephone representatives and there are many pharmaceutical companies that would like to utilize our sales force as an extension of their own sales and marketing efforts."

"We are very pleased with the in-roads Superior has made in the distribution of Gensia's fine products," said Robert Cusick, CEO of DynaGen. "Additionally, this shows Superior's distribution capabilities and why they will play an integral part in the DynaGen business plan."

DynaGen Inc.'s (OTC BB:DYGN) strategy is to become a leading developer, manufacturer and distributor of generic pharmaceutical products. Over the past two years, the company has made several strategic acquisitions including Able Laboratories Inc., a manufacturer of pharmaceuticals, as well as Superior Pharmaceutical Co. and Generic Distributors Inc. (GDI), both of which are pharmaceutical distributors.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release (as well as information included in oral statements or other written statements made or to be made by DynaGen Inc.) contains statements that are forward-looking, such statements related to consummation of the transaction, anticipated future revenues of the companies and success of current product offerings. There is no assurance that the company will be able to develop new products or that such products will benefit from Superior's distribution capabilities. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of DynaGen Inc. For a description of additional risks and uncertainties, please refer to DynaGen Inc., filings with the Securities and Exchange Commission, including Forms 10K and 10Q.